COPD is a leading cause of morbidity and mortality worldwide. Long-term cigarette smoking is the cause of > 90% of COPD cases in Westernized countries. However, only a fraction of chronic heavy smokers develop symptomatic COPD by age 80. COPD is characterized by an abnormal immune response in the lower airways, and its progression is associated with infiltration of the lung by innate and adaptive inflammatory immune cells that form lymphoid follicles. There is growing evidence that both cellular-and antibody-mediated autoimmunity has a fundamental role in the pathogenesis of stable COPD. In particular, carbonyl-modified proteins may help to drive autoimmunity in COPD and cause the characteristic small airways abnormalities and even contribute to the pathogenesis of pulmonary emphysema. Although direct, indirect, and circumstantial evidence of a role for autoimmunity in stable patients with COPD has been identified, no cause-and-effect relationship between autoimmunity and the mechanisms of Normal adult human lungs contain w30 Â 10 9 lymphocytes, representing 7% of the total number of lymphocytes in the body. The lungs therefore represent a major lymphoid organ with a complex functional organization that is only partially understood.
number of lymphocytes in the body. The lungs therefore represent a major lymphoid organ with a complex functional organization that is only partially understood. 1, 2 There is a prevalence of CD3 þ T cells, that, together with the gut, compose w14% to 15% of the total number of CD4 þ and CD8 þ cells of the body. 2, 3 The CD4 þ / CD8 þ lung ratio is w1, with a high prevalence of CD103 þ /integrinb7 memory T cells but with only a minority of CD3 þ TCRgd þ (gdT) cells. 3, 4 The latter can influence B-cell differentiation, control levels of circulating immunoglobulins, and affect autoantibody production. 5 Both CD27 
CD103
-effector memory cells are also abundant in the lung. 4 T-helper (Th) cells cannot be easily separated into distinct lineages in human tissues because they often secrete multiple Th cellassociated cytokines. However, Th1 interferon (IFN)-g þ cells are found at the highest frequencies in the normal human lung. 4 It is noteworthy that only a small fraction (< 6%) of these Th cells are IL-4 þ (Th2), IL-9 þ (Th9), IL-10 þ (Th10), IL-17A þ (Th17), or IL-22 (Th22), whereas around 50% of the Th cells are granulocyte-macrophage colony-stimulating factor þ that may protect against autoimmune diseases. 4, 6 Th17 cells may play a pathogenic role in autoimmune diseases through the actions of IL-17A, IL-21, and IL-22, whereas CD4 þ /CD25 þ forkhead box P3 þ T-regulatory cells are critical for sustaining immune tolerance through IL-10 and transforming growth factor-b production. Constitutive bronchus-associated lymphoid tissue (BALT) is not usually present in healthy human adults. Inducible BALT (iBALT), an ectopic tertiary lymphoid structure composed of highly organized T-and B-cell zones with proliferating lymphocytes that form in the lung in response to inflammation, including autoimmunity, can be found throughout the human lung. Both BALT and iBALT acquire antigens from the airways and initiate local immune responses maintaining memory cells in the lung. 8 Autoimmune Responses in Stable COPD Pathogenesis COPD, a leading cause of morbidity and mortality worldwide, is caused by complex interactions between environmental factors (particularly cigarette smoking) and genetic factors. Long-term cigarette smoking causes >90% of COPD in Westernized countries; however, only a fraction of chronic heavy smokers develop symptomatic COPD by age 80. 9 The progressive chronic airflow limitation in COPD is due to two major pathological processes: (1) remodelling and narrowing of small airways and (2) destruction of the lung parenchyma with consequent loss of the alveolar attachments of these airways from pulmonary emphysema. This results in diminished lung recoil, higher resistance to flow, and closure of small airways at higher lung volumes during expiration, with consequent air trapping in the lung. This leads to the characteristic hyperinflation of the lungs, which gives rise to the sensation of dyspnea and decrease exercise tolerance. Both the small-airway remodelling and narrowing and the pulmonary emphysema are likely to be the results of chronic lung inflammation.
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COPD is characterized by an abnormal immune response in the lower airways, with disease progression associated with infiltration of innate and adaptive inflammatory immune cells that form lymphoid follicles (LF). For this reason, the inflammatory response present in the lower airways of stable COPD is considered an amplification of the inflammatory response to smoking seen in smokers with normal lung function. 9 LF are rarely observed in the small airways of nonsmokers, but they are present in the small airways of approximately 5% of smokers with normal lung function and in smokers with mild to moderate COPD. Their prevalence increases sharply to 25% to 30% in severe and very severe COPD for unclear reasons. The LF in the small airways of patients with COPD are large aggregates of B cells, with interspersed CD21 þ and CD35 þ follicular dendritic cells surrounded by lower numbers of CD4 þ (80%-90%) and few CD8 þ T cells.
9,10
The major T-and B-cell subsets involved in the pathogenesis of stable COPD (cell type and related functions) are summarized in Table 1 . 9, 10 There is growing evidence that autoimmunity has a role in the pathogenesis of stable COPD. Although direct, indirect, and circumstantial evidence of a role for autoimmunity in stable COPD has been identified (Fig 1) , no cause-and-effect relationship between autoimmunity and COPD mechanisms has been established 11 and
represents an area of intense active research.
We will not discuss data on COPD exacerbations because of the absence of studies showing a role of autoimmunity in the pathogenesis of COPD exacerbations.
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B Cells and Autoantibody-Mediated Lung Damage in Stable COPD Pathogenesis
More than half of a century after the first demonstration of the presence of serum antibodies reactive against human lung tissues in patients with "idiopathic obstructive emphysema," 12 the role of B cells and autoantibodies in the pathogenesis of stable COPD is still unknown. Although pulmonary emphysema usually only appears with increasing COPD severity, it can also occur in patients without airflow obstruction. 9, 10 Most of the evidence supporting the presence of an autoantibody-mediated autoimmune response in stable patients with COPD has been gathered from studies of the more advanced grades of diseases often associated with significant pulmonary emphysema. This suggests that autoantibodies may contribute to the pathogenesis of pulmonary emphysema.
B cells localized in the peripheral lung of stable COPD are mainly IgM-bearing and IgD-negative, which suggests a degree of activation. Moreover, a predominant part of these cells is CD27 þ , a marker for memory B cells. In one study in which LF were isolated from the small airways of stable patients with COPD, oligoclonal B cells were found, suggesting that they play a role in local antigen-specific autoimmune responses. 9 B cells organized in iBALT structures and macrophages accumulate in the lungs and contribute to cigarette smoke (CS)-induced pulmonary emphysema. B celldeficient mice are significantly protected against CS-induced emphysema. 13 Natural (because they are produced at birth in the absence of exposure to foreign antigens) IgM autoantibodies are present in the serum of the normal subjects and show poly-reactivity with low binding affinity, but with high avidity. This response provides time for the adaptive immune system to mount a highly specific immune response to foreign antigens, lessening the necessity to produce highly specific IgG autoantibodies, with the potential of causing autoimmune disease owing to their high-affinity binding.
14 Serum and/or lung IgM, IgG, and, less frequently, IgA autoantibodies are often (but not always) found in both smokers with normal lung function and stable patients with COPD. These are not disease-specific, being directed against rheumatoid factor, nuclei, lung, lower airway epithelium (including their cytokeratin 18 and 19), endothelium, anticyclic citrullinated peptide, and/or extracellular matrix components (such as elastin, collagen I and V, and decorin) and many other epitopes (eg, mutated citrullinated vimentin or CD80). In most cases, their presence significantly correlates with smoking rather than with the degree of airflow limitation. 9, [15] [16] [17] [18] [19] [20] Carbonyl-modified proteins, arising from oxidative/ nitrosative stress (Fig 2) , promote serum autoantibody production in stable COPD. 21 The B-cell activating factor (BAFF, also termed B-lymphocyte stimulator), belongs to the tumor necrosis factor family and is responsible for B-cell survival and maturation; its overexpression is associated with autoimmune diseases.
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BAFF is overexpressed in bronchiolar LF and in the small airways of stable patients with COPD compared with control nonsmokers, but not in control smokers with normal lung function. BAFF overexpression creates a selfperpetuating loop contributing to COPD progression by promoting pulmonary B-cell survival and LF expansion. 24 Antagonizing BAFF in CS-exposed mice attenuates pulmonary inflammation and alveolar destruction. 25 IL-6 (originally identified as a B-cell differentiation factor) is a multifunctional cytokine that may contribute to the pathogenesis of the autoimmune response observed in the lungs of severe stable patients with COPD. 9, 26 IL-17A in the peripheral lung of patients with advanced COPD may contribute to disease progression and the development of lymphoid follicles via activation of CXCL12. 27 A major source of IL-17A is the CD4 autoantibodies. An imbalance of the microbiome has been recently reported in bronchial biopsies of stable patients with COPD. 29, 30 Cell-Mediated Autoimmune Lung Damage in Stable COPD Pathogenesis
There is evidence that stable COPD may be caused by T-cell inflammation and autoimmunity derived from an increased number of activated signal transducer and activator of transcription-4 and IFN-g CD4þ T cells in bronchial biopsies and BAL that correlate with decreasing lung function. 31 This evidence indicates that activated T cells, through Th1 cytokines, along with CD8 þ T cells and innate immune cells recruited by Th1 cytokines, damage the lung. 32 Subsequently, severe emphysema has been associated with lung oligoclonal CD4 þ and CD8 þ T cells 33, 34 and the presence of ADCC against bronchial epithelium in stable COPD. 17 In addition, in animal models chronic CS exposure generates pathogenic T cells inducing a COPD-like disease.
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Cytotoxic pro-inflammatory CD8 þ T cells and CD8 þ NKT-like cells are increased in the peripheral blood and airways of patients with COPD, but only in the lungs of smokers with normal lung function. In COPD, these senescent cells express increased levels of the cytotoxic mediators perforin and granzyme B and the pro-inflammatory cytokines IFN-g and tumor necrosis factor-a and have increased cytotoxicity toward lung epithelial cells. 36 Production of these pro-inflammatory mediators by lung-resident CD8 þ T cells may contribute to the pathogenesis of stable COPD. 9, 26 In animal models of emphysema, there is persistence of lung oligoclonal CD8 þ T cells upon smoking cessation. 37 This may lead to chronic activation of macrophage subtypes that preclude proper healing of the lung and thereby contribute to pulmonary emphysema. 38 
Diagnostic Implications
Autoantibodies may play a pathogenic role in the pathogenesis of COPD progression and in the pathogenesis of autoimmune emphysema (Fig 3) . Furthermore, serum autoantibodies may act as biomarkers to predict clinical phenotypes or progression of stable COPD. A US patent application (20160097778) has been filled for a method for determining COPD progression (and thus prognosis) and/or in selecting a personalized treatment made on the basis of measuring serum autoantibody response to carbonylated vimentin (an intracellular intermediate filament expressed in mesenchymal cells) (http://www.freepatentsonline.com/ y2016/0097778.html). Figure 2 -Oxidative (ROS) and nitrosative (RNS) stress from environmental (eg, cigarette smoking, air pollution, indoor biomass smoke) and endogenous sources (eg, MPO, mitochondrial respiration, nicotinamide adenine dinucleotide phosphate reduced oxidase complex, xanthine oxidase) may causes direct tissue damage through lipids, proteins, carbohydrates, and DNA damage. This may also cause the formation of carbonyl stress that through posttranslational, nonenzymatic modifications on proteins that can alter their function and result in the formation neo-autoantigens triggering an autoimmune response in the lower airways of smokers that in susceptible subjects is associated with a slowly progressive damage of the lower airways and development of COPD. MPO ¼ myeloperoxidase; NADPH ¼ nicotinamide adenine dinucleotide phosphate-oxidase; RNS ¼ reactive nitrogen species; ROS ¼ reactive oxygen species.
Therapeutic Implications
In contrast to asthma, glucocorticoid treatment of stable COPD is rather ineffective in reducing airway inflammation and lung function decline 39 ; however, long-term withdrawal of inhaled glucocorticoids in stable patients with COPD results in a significant rise in the number of CD3 þ , CD4 þ , and CD8 þ T cells in the bronchial mucosa. 40 Inhaled glucocorticoids may reduce the adaptive immune response in stable COPD and may be more effective in patients with an increased B-cell response indicated by high autoantibody titer. 41 Unfortunately, this may also account for the small but increased risk of pneumonia observed in stable patients with COPD on high-dose inhaled glucocorticoids. 26, 39 Macrolide antibiotics, such as azithromycin and erythromycin, have immunomodulatory/antiinflammatory effects. 42 Long-term treatment with these drugs reduces the frequency of exacerbations in patients with moderate to very severe COPD and a history of frequent exacerbations 43 ; however, this is associated with an increased risk of adverse events and emergence of macrolide-resistance. As a result, non-antibiotic macrolides with immunomodulatory/antiinflammatory effects are in preclinical development. 42, 44 In addition, there are many potential anti-B-cell-directed therapies that are in clinical use for the treatment of autoimmune diseases that have potential for treating stable patients with COPD. B-cell depletion by anti-CD20 monoclonal antibodies (mAbs) rituximab, ocrelizumab, and ofatumumab have efficacy in multiple sclerosis.
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CD20 regulates cell-cycle progression in B cells; in mice, loss of CD20 functions leads to a 20% to 30% reduction in B-cell numbers with low serum IgG and normal IgM levels. 46 Epratuzumab is a B cell-directed nondepleting anti-CD22 mAb that results in reduced B-cell receptor complex signalling by intensifying the normal inhibitory role of CD22 on the B-cell receptor and diminishing B-cell activation epratuzumab is in phase III clinical trials in patients with systemic lupus erythematosus. 47 BAFF plays a central role in the induction and maintenance of CS-induced pulmonary autoantibodies, suggesting a therapeutic potential for BAFF blockade in limiting autoimmune processes associated with smoking. 48 Belimumab, a mAb anti-BAFF (reducing B-cell differentiation and survival) is the first drug to be approved specifically for the treatment of systemic lupus erythematosus in more than 50 years. 49 Anti-IL-6 blocking mAbs (including siltuximab and tocilizumab), although used in clinical trials of rheumatoid arthritis and cancers, have not been tested in patients with COPD. 26, 39 Secukinumab and ixekizumab are mAbs that selectively bind and neutralize IL-17A blocking its binding to the IL-17 receptor and have been approved for the treatment of psoriasis. 50 However, CNTO 6785, another anti-IL-17A mAb, was ineffective in a phase II randomized controlled trial of stable COPD. 51 Brodalumab, a mAb-blocking IL-17 receptor a, has been tested in patients with severe asthma. 26, 39 IL-23, a key regulator of Th17 cells, can be inhibited by specific mAbs (guselkumab and tildrakizumab) or ustekinumab, which blocks the shared p40 component of IL-12 and IL-23. These are all effective in the treatment of psoriasis. 26, 39 Low-molecular-weight, cell-permeable RORC2 antagonists and novel RORC2-independent modulators of IL-17A have been identified. 52 In addition, statin treatment reverses the IL-17A/IL-10 imbalance in the airways of stable patients with COPD but, unfortunately, statins are clinically ineffective in the long-term treatment of these patients. 26 Anti-CD3 (expressed on w90% of lung T cells) mAbs effectively treat autoimmune disease in animal models and show promise in clinical trials. The development of tolerance by anti-CD3 mAbs is related to the induction of T-regulatory cells. 53 It is unlikely that mouse models of COPD will be more predictive than those reported to date. This demands testing of novel therapies in randomized controlled trials in patients with stable COPD to demonstrate efficacy on COPD exacerbations and disease progression. Close monitoring of infectious and noninfectious adverse chestjournal.org events is mandatory. In fact, blocking immune responses might be associated with reduced immunity to infections.
Conclusions
There is growing evidence that ultimately, autoimmunity, like so many other facets of pathophysiology linked with COPD, is likely to play a more central role in the progression of the disease in certain subgroups of patients with COPD rather than a unifying central across all COPD. Both antibody-and cell-mediated responses appear to be involved in autoimmune responses and in the development of lung damage. In particular, carbonyl-modified proteins may drive autoimmune mechanisms in COPD, causing the characteristic small airways abnormalities and pulmonary emphysema. Drugs that target this autoimmune response are available, and the results of controlled clinical trials are awaited with great interest. The potential for measuring specific serum autoantibodies as biomarkers to predict clinical phenotypes, progression of stable COPD or drug response is promising.
